论文部分内容阅读
目的：肾移植病人服用环孢霉素A易诱发高血压症和产生肾毒性。钙通道阻滞剂对移植术后高血压症有良好的降压作用。本实验，我们研究尼卡地平用于肾移植病人的长期疗效。方法：41例肾移植病人随机分为二组：尼卡地平为治疗组；硝苯地平为对照组。进行长达二年以上的临床观察。两组病人年龄、性别、体重、临床指征无显著差异。结果：显示尼卡地平干扰环孢霉素A(CsA)代谢，导致CsA剂量降低30%，但未见其增强CsA肾毒性。结论：本实验结果提示尼卡地平用于肾移植并发高血压症病人安全有效，并能节约肾移植病人的费用。
Purpose: Renal transplant patients taking cyclosporin A can induce hypertension and renal toxicity. Calcium channel blockers have a good antihypertensive effect on post-transplant hypertension. In this experiment, we studied the long-term efficacy of nicardipine in patients with kidney transplantation. Methods: Forty-one patients with renal allograft were randomly divided into two groups: nicardipine treatment group and nifedipine control group. For more than two years of clinical observation. Two groups of patients age, gender, weight, clinical indications no significant difference. Results: Nicardipine was shown to interfere with cyclosporine A (CsA) metabolism, resulting in a 30% reduction in CsA dose but no enhancement of CsA nephrotoxicity. Conclusion: The results of this study suggest that nicardipine is safe and effective for renal transplantation patients with hypertension and can save the cost of renal transplant patients.